INTRODUCTION
Oncodermatology is an emerging, growing field of Dermatology aiming to provide supportive care to cancer patients and to prevent unnecessary interruption of cancer treatment. Dermatologic conditions are increasingly prevalent among patients with hematological malignancies. Phillips et al reported that hemato-oncology patients were 6 times more like to receive dermatological consultations compared with patients with non-hematological malignancies.1 This occurrence can be attributed to factors such as immunosuppression and exposure to multiple therapeutic agents. In addition, the introduction of novel therapies is likely contributing to this trend. The impact of dermatologic disease on cancer treatment outcomes, along with its potential to cause significant morbidity and mortality, underscores the crucial role of oncodermatology in the care of patients with hematology-oncology conditions.
The primary objective was to quantify and analyze dermatologic conditions observed in patients with hematology-oncology diagnoses at a central London tertiary hospital. The secondary objective was to explore potential associations between these conditions and specific subtypes of hematologic malignancies, as well as the anticancer therapies employed.
The primary objective was to quantify and analyze dermatologic conditions observed in patients with hematology-oncology diagnoses at a central London tertiary hospital. The secondary objective was to explore potential associations between these conditions and specific subtypes of hematologic malignancies, as well as the anticancer therapies employed.
MATERIALS AND METHODS
We conducted a retrospective, single-center review to analyze acute hematology-oncology referrals received by our on-call dermatology service between August 2020 and November 2022. Data were collected from inpatient notes, clinic letters, and histopathology reports available in the electronic patient record system.
RESULTS
A total of 134 patients were referred to the dermatology department from the hematology-oncology department. Patient ages ranged from 13 to 88 years, with a median age of 54 years. The cohort included 58 males and 76 females (male-to-female ratio, 1:1.3).
Hematologic malignancies were classified as lymphoid neoplasms (45%), myeloid neoplasms (29%), plasma cell dyscrasias (13%), Hodgkin lymphoma (6%), and other malignant or nonmalignant diagnoses (7%). The most common diagnosis
Hematologic malignancies were classified as lymphoid neoplasms (45%), myeloid neoplasms (29%), plasma cell dyscrasias (13%), Hodgkin lymphoma (6%), and other malignant or nonmalignant diagnoses (7%). The most common diagnosis
